TREATMENTS for different types of cancer and a life-threatening fungal infection are among those to have been accepted for use on the NHS in Scotland.
The Scottish Medicines Consortium (SMC) has accepted five medicines in its latest round of decisions, including a “game-changer” treatment for some prostate cancer patients and a drug for lung cancer patients.
Selinexor, also known as Nexpovio, has been accepted for treating adults with multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow.
READ MORE: John Swinney announces fund to restore Scottish town's historic pier
It can be used together with bortezomib and dexamethasone for patients who have already received at least one line of treatment or with dexamethasone in those who have already received four lines of treatment.
Pembrolizumab, also known as Keytruda, has been accepted for the treatment of adults with non-small cell lung cancer who are at high risk of recurrence following surgery and chemotherapy.
Relugolix, also known as Orgovyx, has been accepted for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Prostate Cancer UK welcomed the decision as a “game-changer”.
Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: “It’s wonderful news that Relugolix has been approved for potentially thousands of men in Scotland with advanced prostate cancer – meaning that the treatment is now accessible across the whole of the UK.
“This drug is a game-changer: not only is it an effective way to keep cancer under control, it makes the treatment experience far more convenient and comfortable.
“A man on Relugolix can take it as a tablet at home, so he doesn’t need to make multiple trips to the clinic, and it’s especially beneficial to men who aren’t able to have injections. What’s more, trials suggest it has a lower risk of heart problems that are sometimes associated with these sorts of treatments.
READ MORE: Police probe as 'historic' listed building demolished without consent
“Sadly, in Scotland, more than one in three men with prostate cancer are diagnosed when their disease is advanced. Today’s decision is a huge step forward for these men – bringing them a kinder, effective treatment option to keep cancer at bay.”
The SMC also accepted Rezafungin acetate, also known as Rezzayo, for the treatment of adults with invasive candidiasis, a type of life-threatening fungal infection.
Faricimab, also known as Vabysmo, was accepted for the treatment of adult patients with visual impairment due to swelling of the macula, a part of the retina, caused by a blockage in the blood flow in a vein of the retina.
SMC chairman Dr Scott Muir said: “The committee is pleased to be able to accept these new medicines for use by NHS Scotland.
“Selinexor offers an additional treatment option for patients with multiple myeloma, allowing more personalised treatment.
“Pembrolizumab will provide a treatment for people who have had surgery to remove lung cancer but are at a high risk of the cancer coming back.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here